Search Result
Results for "
Fatty Acid Amide
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-N2327
-
|
|
Endogenous Metabolite
|
Others
|
|
Oleamide is an endogenous fatty acid amide which can be synthesized de novo in the mammalian nervous system, and has been detected in human plasma.
|
-
-
- HY-14595
-
-
-
- HY-B0182
-
-
-
- HY-121389
-
|
PalmitAmide
|
Bacterial
NF-κB
PPAR
|
Infection
Inflammation/Immunology
|
|
Hexadecanamide (Palmitamide) is a fatty acid amide that has orally active anti-allergic, antioxidant, and neuroprotective effects. Hexadecanamide exerts protective effects in Staphylococcus aureus- and SARA-induced mastitis. Hexadecanamide suppresses S. aureus-induced activation of the NF-κB pathway and improves blood-milk barrier integrity. Hexadecanamide activates PPARα. Hexadecanamide enhances sperm motility in vitro. Hexadecanamide can be studied in research for mastitis and asthenozoospermia .
|
-
-
- HY-W130610
-
|
|
Liposome
Akt
mTOR
|
Others
|
|
Stearamide is a primary fatty acid amide. Stearamide displays cytotoxic and ichthytoxic activity .
|
-
-
- HY-14380
-
PF-3845
2 Publications Verification
|
FAAH
Autophagy
|
Inflammation/Immunology
Cancer
|
|
PF-3845 is a potent, selective, irreversible and orally active inhibitor of fatty acid amide hydrolase (FAAH), with a Ki of 0.23 μM. PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile. PF-3845 can reduce pain sensation, inflammation, and anxiety/depression without substantial effects on motility or cognition .
|
-
-
- HY-119283
-
-
-
- HY-15250
-
JZL195
4 Publications Verification
|
FAAH
MAGL
Autophagy
|
Neurological Disease
|
|
JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC50s of 2 and 4 nM, respectively .
|
-
-
- HY-N2365
-
|
N-BenzylpalmitAmide; N-BenzylhexadecanAmide; MacAmide 1
|
FAAH
Autophagy
|
Others
|
|
Macamide B (N-Benzylhexadecanamide; Macamide 1) is a macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH).
|
-
-
- HY-19740
-
-
-
- HY-110138
-
|
|
FAAH
|
Others
|
|
PDP-EA is a compound that increases the amidohydrolase activity of FAAH (fatty acid amide hydrolase) .
|
-
-
- HY-10865
-
|
|
FAAH
Autophagy
|
Neurological Disease
|
|
LY2183240 is a highly potent blocker of anandamide uptake (IC50= 270 pM; Ki=540 nM). LY2183240 is a potent, covalent inhibitor of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) with an IC50 of 12.4 nM. LY2183240 inactivates FAAH by carbamylation of the enzyme's serine nucleophile. LY2183240 also inhibits several other brain serine hydrolases with IC50s of 5.3, 0.09, 8.2 nM for MAG lipase, bh6 and KIAA1363, respectively .
|
-
-
- HY-117401
-
|
|
Fluorescent Dye
|
Others
|
|
5-Dodecanoylaminofluorescein is an amphipathic (amphoteric) fluorescent probe (Ex/Em = 485 nm/515-535 nm), which consists of a hydrophilic fluorescein core and a hydrophobic dodecanoyl group (C12 fatty acid chain) linked by an amide bond. 5-Dodecanoylaminofluorescein is mainly used as an interface-localized radical trapping/indicator probe. Dodecanoylaminofluorescein can be used for the determination of the antioxidant properties of emulsions, or can serve as a lipophilic drug model for the study of passive skin penetration when encapsulated in tyrosine-derived nanospheres .
|
-
-
- HY-N6723
-
|
|
Ceramidase
Acyltransferase
|
Infection
Cancer
|
|
Fumonisin B2 is a selective ceramide synthase inhibitor and carcinogenic mycotoxin with toxicity comparable to that of Fumonisin B1 (HY-N6719). Fumonisin B2 inhibits de novo sphingolipid biosynthesis by blocking the amide bond formation between fatty acids and dihydrosphingosine, which leads to a massive intracellular accumulation of free dihydrosphingosine, altered sphingosine levels, subsequent inhibition of cell proliferation, and induction of cell death. Fumonisin B2 is used to investigate the pathogenesis of diseases associated with Fusarium verticillioides contamination, including equine leukoencephalomalacia, porcine pulmonary edema syndrome, human esophageal cancer, and rat hepatocellular carcinoma .
|
-
-
- HY-18081
-
-
-
- HY-N7062
-
|
Takeda-25
|
FAAH
|
Neurological Disease
|
|
JNJ-1661010 (Takeda-25) a potent and selective fatty acid amide hydrolase (FAAH) inhibitor with IC50s of 34 and 33 nM for rat FAAH and human FAAH, respectively. JNJ-1661010 can cross the blood-brain barrier and used as broad-spectrum analgesics .
|
-
-
- HY-120961
-
|
N-EthyloleAmide
|
FAAH
|
Metabolic Disease
|
|
Oleoyl ethyl amide (N-Ethyloleamide) is a fatty acid amide hydrolase (FAAH) inhibitor. Oleoyl ethyl amide can counteract bladder overactivity .
|
-
-
- HY-125967
-
|
|
FAAH
|
Neurological Disease
|
|
AM 374 is an fatty acid amide hydrolase (FAAH) inhibitor. AM 374 inhibits amidase activity with an IC50 value of 13 nM. AM 374 can be used for the research of neurological disease .
|
-
-
- HY-101457
-
|
|
MAGL
|
Metabolic Disease
|
|
JZP-430 is a potent, highly selective, irreversible inhibitor of α/β-hydrolase domain 6 (ABHD6) with an IC50 of 44 nM, exhibits ~230-fold selectivity over fatty acid amide hydrolase (FAAH) and lysosomal acid lipase (LAL) .
|
-
-
- HY-101722
-
|
AC 223; DL-N-(α-Methylbenzyl)linoleAmide
|
Acyltransferase
|
Metabolic Disease
|
|
Melinamide, an amide derivative of an unsaturated long-chain fatty acid, is an inhibitor of cholesterol absorption with an IC50 of 20.9 μM.
|
-
-
- HY-120957
-
|
AMC-AA; 7-Amino-4-methyl coumarin-arachidonAmide
|
Endogenous Metabolite
|
Metabolic Disease
|
|
AMC arachidonoyl amide (AMC-AA) is one of several fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity.1 FAAH is a relatively unselective enzyme in that it accepts a variety of amide head groups other than the ethanolamine of its nominal endogenous substrate anandamide.2 Exposure of AMC-AA to FAAH activity results in the release of the fluorescent aminomethyl coumarin that absorbs at 360 nm and emits at 465 nm. This allows the fast and convenient measurement of FAAH activity using a simple cuvette or microplate fluorometer.
|
-
-
- HY-103462
-
-
-
- HY-121422
-
|
|
MAGL
Histamine Receptor
|
Inflammation/Immunology
|
|
JZP-361 is a potent, reversible and selective inhibitor of human recombinant MAGL (hMAGL) with an IC50 of 46 nM. JZP-361 also shows antihistaminergic activities and can be used for asthma research .
|
-
-
- HY-169794
-
|
|
DNA/RNA Synthesis
|
Others
|
|
N-Palmitoyl-phenylalanine is an N-acyl amide that contains the long-chain saturated fatty acid Palmitic acid (HY-N0830) conjugated via an amide bond to the essential amino acid L-Phenylalanine (HY-N0215). N-Palmitoyl-phenylalanine inhibits pre-mRNA splicing in HeLa cell nuclear lysates (IC50 > 400 μM) but has no splicing activity in intact HeLa cells .
|
-
-
- HY-118158
-
|
|
FAAH
|
Neurological Disease
|
|
FAAH/MAGL-IN-4 (Compound 13) is a potent fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) inhibitor with IC50s of 9.1 nM and 7.9 μM, respectively. FAAH/MAGL-IN-4 can be used for the research of pain and CNS disorders .
|
-
-
- HY-164495
-
|
|
FAAH
Thyroid Hormone Receptor
|
Inflammation/Immunology
Endocrinology
|
|
Sob-AM2 is a potent substrate (Km=1.3 μM) targeting fatty acid amide hydrolase (FAAH) expressed in the brain and has blood-brain barrier permeability. Sob-AM2 delivers high concentrations of Sobetirome (HY-14823) to the central nervous system with minimal peripheral systemic dose, thereby stimulating central thyroid hormone receptor β (TRβ). In addition, Sob-AM2 can prevent myelin and axon degeneration in experimental autoimmune encephalomyelitis (EAE) mice .
|
-
-
- HY-123863
-
|
|
FAAH
|
Neurological Disease
|
|
SSR411298 is an orally active, selective and reversible fatty acid amide hydrolase (FAAH) inhibitor. SSR411298 has the potential for post-traumatic stress disorder research .
|
-
-
- HY-152251
-
|
|
Cannabinoid Receptor
FAAH
|
Inflammation/Immunology
|
|
CB2R/FAAH modulator-1 is a cannabinoid type 2 receptor (CB2R) full agonist with Kis of 14.8 nM and 241.3 nM for CB2R and CB1R, respectively. CB2R/FAAH modulator-1 is a fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 4 μM. CB2R/FAAH modulator-1 decreases pro-inflammatory and increases anti-inflammatory cytokines production .
|
-
-
- HY-W130610R
-
|
|
Liposome
Reference Standards
Akt
mTOR
|
Others
|
|
Ginsenoside C-K (Standard) is the analytical standard of Ginsenoside C-K. This product is intended for research and analytical applications. Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing iNOS and COX-2. Ginsenoside C-K exhibits an inhibition against the activity of CYP2C9 and CYP2A6 in human liver microsomes with IC50s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.
|
-
-
- HY-127061
-
-
-
- HY-124081
-
|
|
Apoptosis
|
Metabolic Disease
|
|
N-Oleoyl-L-Serine is an endogenous amide of long-chain fatty acids with ethanolamine (N-acyl amides). N-Oleoyl-L-Serine is a lipid regulator of bone remodeling and stimulates osteoclast apoptosis. N-Oleoyl-L-Serine can be used for antiosteoporotic drug discovery development .
|
-
-
- HY-14595R
-
|
4-Methylgenistein(Standard); Olmelin (Standard)
|
Reference Standards
FAAH
Autophagy
Endogenous Metabolite
|
Neurological Disease
Cancer
|
|
Biochanin A (Standard) is the analytical standard of Biochanin A. This product is intended for research and analytical applications. Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC50s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.
|
-
-
- HY-103337
-
|
Arachidonyl serotonin; AA-5-HT
|
FAAH
TRP Channel
|
Neurological Disease
|
|
N-Arachidonoylserotonin (Arachidonyl serotonin; AA-5-HT) is a potent fatty acid amide hydrolase (FAAH) inhibitor with an IC50 value of 1~12 µM. N-Arachidonoylserotonin acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels (IC50=70~100 nM). N-Arachidonoylserotonin is analgesic in rodents .
|
-
-
- HY-W751418
-
|
(Z)-2-tetracos-15-enamidoethanesulfonic Acid
|
FAAH
|
Neurological Disease
|
|
N-Nervonoyl taurine ((Z)-2-tetracos-15-enamidoethanesulfonic acid) is a fatty acid-taurine conjugate derived from nervonic acid. N-Nervonoyl taurine is a substrate of fatty acid amide hydrolase (FAAH) discovered during metabolite profiling .
|
-
-
- HY-18080
-
-
-
- HY-111389
-
|
|
FAAH
Autophagy
|
Metabolic Disease
|
|
FAAH-IN-1 is a fatty acid amide hydrolase (FAAH) inhibitor, with IC50s of 145 nM and 650 nM for rat and human FAAH, respectively.
|
-
-
- HY-N3033
-
|
|
FAAH
Autophagy
|
Metabolic Disease
|
|
N-Benzyllinolenamide is a natural macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 41.8 μM .
|
-
-
- HY-32952
-
|
6-Fluoropyridine-3-boronic Acid
|
Drug Intermediate
|
Others
|
|
2-Fluoropyridine-5-boronic acid (6-Fluoropyridine-3-boronic acid) is a drug intermediate that can be used in the synthesis of fatty acid amide hydrolase inhibitors and pyrethroid derivatives .
|
-
-
- HY-144738
-
|
|
Epoxide Hydrolase
FAAH
|
Inflammation/Immunology
|
|
Dual FAAH/sEH-IN-1 (compound 3) is a high affinity dual sEH (soluble epoxide hydrolase) and FAAH (fatty acid amide hydrolase) inhibitor, with IC50 values of 9.6 and 7 nM, respectively. Dual FAAH/sEH-IN-1 shows antinociception against the inflammatory phase .
|
-
-
- HY-103461
-
|
|
FAAH
|
Neurological Disease
|
|
FAAH-IN-6 (compound 21d) is a potent, orally active and cross the blood-brain barrier fatty acid amide hydrolase (FAAH) inhibitor with IC50s of 0.72, 0.28 nM for hFAAH, rFAAH, respectively. FAAH-IN-6 shows dose-dependent analgesic efficacy in animal models of both neuropathic and inflammatory pain .
|
-
-
- HY-118210
-
|
|
FAAH
|
Metabolic Disease
|
|
PHOP is a fatty acid amide hydrolase (FAAH) inhibitor used to assess inhibitory activity in a fluorometric assay. PHOP can determine FAAH activity by measuring the amount of 4-pyridin-1-ylbutyric acid released by the enzyme in rat brain microsomes. PHOP demonstrates potential as a FAAH inhibitor and can directly measure FAAH activity by reversed-phase HPLC and fluorescence detection, providing a basis for the development of new inhibitors.
|
-
-
- HY-126720
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
N-Lignoceroyl Taurine is an arachidonoyl amino acid and taurine conjugate with a fatty acid that can be isolated from bovine brain. N-Lignoceroyl Taurine is one of several novel taurine-conjugated fatty acids discovered during mass spectrometry lipidomic analysis of the brain and spinal cord of wild-type and fatty acid amide hydrolase (FAAH) knockout mice. N-Lignoceroyl Taurine levels were 23-26-fold higher in FAAH -/- mice compared to wild-type mice, suggesting that FAAH utilizes N-Lignoceroyl Taurine as a substrate. However, in vitro experiments with purified FAAH showed that N-Lignoceroyl Taurine was hydrolyzed 2,000-fold slower in FAAH compared to oleoylethanolamide. N-Acyl Taurines with polyunsaturated acyl chains can activate members of the transient receptor potential (TRP) calcium channel family, including TRPV1 and TRPV4.
|
-
-
- HY-138693
-
|
|
FAAH
|
Neurological Disease
|
|
ST4070 is a potent, orally active, and selective reversible fatty acid amide hydrolase (FAAH) inhibitor. ST4070 increases endocannabinoid (eCB) brain levels and counteracts neuropathic pain in animal models. ST4070 enhances the endogenous eCB tone in specific brain regions engaged in emotional control, and induces remarkable anxiolytic-like behaviours in rodents. ST4070 can be used for neuropathic pain and anxiety disorders research .
|
-
-
- HY-N7214
-
|
|
Others
|
Neurological Disease
|
|
Termitomycamide E is a fatty acid amide that can suppress endoplasmic reticulum stress. Termitomycamide E shows significant protective activity against T. titanicus-toxicity .
|
-
-
- HY-175816
-
|
|
5-HT Receptor
FAAH
Apoptosis
Reactive Oxygen Species (ROS)
|
Neurological Disease
|
|
5-HT6R/FAAH modulator 1 is a selective serotonin 5-HT6 receptor ligand and the fatty acid amide hydrolase (FAAH) enzyme inhibitor. 5-HT6R/FAAH modulator 1 shows a pKi of 6.33 (5-HT6) and a pIC50 valuesof 6.29 (FAAH). 5-HT6R/FAAH modulator 1 also slightly inhibits acetylcholinesterase (AChE) or butyrylcholinesterase (BChE) enzymes (pIC50 = 5.12). 5-HT6R/FAAH modulator 1 can inhibit apoptosis and reduce ROS levels. 5-HT6R/FAAH modulator 1 can be used for the research of neurological disease, such as Alzheimer’s disease (AD) .
|
-
-
- HY-124744
-
|
|
FAAH
|
Neurological Disease
|
|
ASP 8477 is an orally active and selective fatty acid amide hydrolase (FAAH) inhibitor with IC50 values of 3.99, 1.65, and 57.3 nM for human FAAH-1, FAAH-1 (P129T), and FAAH-2, respectively. ASP 8477 has central nervous system activity and can be used in analgesia research .
|
-
-
- HY-127023
-
|
EPA-5-HT
|
Endogenous Metabolite
FAAH
Interleukin Related
Tyrosine Hydroxylase
|
Metabolic Disease
|
|
Eicosapentaenoyl serotonin (EPA-5-HT) is an endogenous fatty acid-serotonin conjugate lipid mediator. Eicosapentaenoyl serotonin acts as an inhibitor of fatty acid amide hydrolase (FAAH). Eicosapentaenoyl serotonin suppresses IL-17 release in Concanavalin A (HY-P2149)-stimulated human peripheral blood mononuclear cells. Eicosapentaenoyl serotonin is regulated by polyunsaturated fatty acids and modulates intestinal immunity and Th17 signaling. Eicosapentaenoyl serotonin can be used for the study of inflammatory bowel disease-related mechanisms .
|
-
-
- HY-10867
-
|
|
FAAH
|
Metabolic Disease
|
|
PF-622 is a selective FAAH inhibitor, and can be used for study of analgesic and anxiolytic/antidepressant .
|
-
-
- HY-158784
-
|
|
FAAH
|
Others
|
|
Arachidonoyl m-Nitroaniline (AmNA) is one of several nitroaniline fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity. Arachidonoyl m-Nitroaniline is a FAAH substrate .
|
-
-
- HY-139384
-
|
|
FAAH
|
Neurological Disease
|
|
FAAH inhibitor 2 (Compound 17b) is an irreversible fatty acid amide hydrolase (FAAH) inhibitor, with an IC50 of 0.153 μM .
|
-
- HY-111199
-
|
|
FAAH
|
Neurological Disease
|
|
JP83 is an irreversible fatty acyl amide hydrolase (FAAH) inhibitor with an IC50 of 1.6 nM in competitive activity-based protein profiling (ABPP) experiments .
|
-
- HY-N2365R
-
|
N-BenzylpalmitAmide (Standard); N-BenzylhexadecanAmide (Standard); MacAmide 1 (Standard)
|
Reference Standards
FAAH
Autophagy
|
Others
|
|
Macamide B (Standard) is the analytical standard of Macamide B. This product is intended for research and analytical applications. Macamide B (N-Benzylhexadecanamide; Macamide 1) is a macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH).
|
-
- HY-146341
-
|
|
FAAH
MAGL
|
Neurological Disease
|
|
FAAH-IN-5 (Compound 7) is a relative selective, irreversible fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 10.5 nM. FAAH-IN-5 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .
|
-
- HY-146342
-
|
|
FAAH
MAGL
|
Neurological Disease
|
|
FAAH/MAGL-IN-3 (Compound 10) is an irreversible fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) dual inhibitor with IC50 values of 179 and 759 nM against FAAH and MAGL, respectively. FAAH/MAGL-IN-3 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .
|
-
- HY-W510032
-
|
Monoethyl nonanedioate; Ethyl hydrogen azelaate
|
Biochemical Assay Reagents
|
Infection
|
|
9-Ethoxy-9-oxononanoic acid is a C-11 fatty acid that has an ethyl ester group at the end of the saturated tail. The carboxylic acid can react with primary amine groups in the presence of activators (e.g. EDC, or HATU) to form a stable amide bond. Azelaic Acid Monoethyl Ester has antifungal activity against Cladosporium herbarum.
|
-
- HY-N2512R
-
|
|
Reference Standards
FAAH
Bacterial
Fungal
Endogenous Metabolite
Autophagy
|
Infection
|
|
1-Monomyristin, extracted from Serenoa repens, inhibits the hydrolysis of 2-oleoylglycerol (IC50=32 μM) and fatty acid amide hydrolase (FAAH) activity (IC50=18 μM). 1-Monomyristin shows antibacterial activity against Staphylococcus aureus and Aggregatibacter actinomycetemcomitans and also antifungal activity against Candida albicans .
|
-
- HY-B0182R
-
-
- HY-N15826
-
|
|
Fluorescent Dye
Ceramidase
|
Cancer
|
|
RBM1-151, a 1-deoxy derivative and vinilog of RBM14-C12 (HY-150163), as a fluorogenic substrate of Amidases (HY-P2736) (Ex/Em). RBM1-151 is hydrolyzed by acid ceramidase (AC) (( appKm = 7.0 μM; appVmax = 99.3 nM/min), N-acylethanolamine-hydrolyzing acid amidase ( appKm = 0.73 μM; appVmax = 0.24 nM/min), and fatty Acid amide hydrolase (FAAH) ( appKm = 3.6 μM; appVmax = 7.6 nM/min) but not by other ceramidases. RBM1-151 is applicable for basic biological studies of lipid amidase function, as well as potential diagnostic/prognostic evaluations of diseases involving dysregulated AC, NAAA, or FAAH (Farber disease, cancer) .
|
-
- HY-133824
-
-
- HY-W009123R
-
|
cis-13-DocosenAmide (Standard)
|
Endogenous Metabolite
Reference Standards
|
Others
|
|
Erucamide (Standard) is the analytical standard of Erucamide. This product is intended for research and analytical applications. Erucamide inhibits intestinal diarrhea.Erucamide also regulates the volume of body fluids in other organs. Erucamide has the ability to promote angiogenesis .
|
-
- HY-161965
-
|
|
FAAH
|
Neurological Disease
|
|
MK-3168 (12C) is a FAAH inhibitor with IC50 values of 1.0, 5.5, 1.7 nM for human, rhesus, rat, respectively. MK-3168 shows good brain uptake and FAAH-specific signal. 11C MK-3168 can be used as FAAH PET tracer .
|
-
- HY-U00240
-
-
- HY-W479534
-
|
DemNA
|
Biochemical Assay Reagents
|
Others
|
|
Decanoyl m-Nitroaniline (DemNA) is a nitroaniline fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity (Ab = 410 nm).
|
-
- HY-120971
-
|
DepNA
|
Endogenous Metabolite
|
Metabolic Disease
|
|
N-Decanoyl p-nitroaniline (DepNA) is one of several nitroaniline fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity.1 FAAH is a relatively unselective enzyme in that it accepts a variety of amide head groups other than the ethanolamine of its endogenous substrate anandamide (AEA). It also will hydrolyze fatty acid amides with fewer carbons and fewer double bonds than arachidonate. Exposure of DepNA to FAAH activity results in the release of the yellow colorimetric dye p-nitroaniline (ε=13,500 at 410 nm). This allows the fast and convenient measurement of FAAH activity using a 96 well plate spectrophotometer.
|
-
- HY-101722R
-
|
AC 223 (Standard); DL-N-(α-Methylbenzyl)linoleAmide (Standard)
|
Acyltransferase
Reference Standards
|
Metabolic Disease
|
|
Melinamide (Standard) is the analytical standard of Melinamide. This product is intended for research and analytical applications. Melinamide, an amide derivative of an unsaturated long-chain fatty acid, is an inhibitor of cholesterol absorption with an IC50 of 20.9 μM.
|
-
- HY-134110
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Anandamide (AEA) is an endogenous cannabinoid that binds to both central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. The biological actions of AEA are terminated by cellular uptake and hydrolysis of the amide bond by the enzyme fatty acid amide hydrolase. Arachidonoyl-N-methyl amide is an analog of anandamide that binds to the human central cannabinoid (CB1) receptor with a Ki of 60 nM. It inhibits rat glial gap junction cell-cell communication 100% at a concentration of 50 μM.
|
-
- HY-134055
-
|
Arachidonic Acid-N,N-dimethyl Amide
|
Cannabinoid Receptor
|
Metabolic Disease
|
|
Anandamide (AEA) is an endogenous cannabinoid that binds to both central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. The biological actions of AEA are terminated by cellular uptake and hydrolysis of the amide bond by the enzyme fatty acid amide hydrolase. Arachidonoyl-N,N-dimethyl amide is an analog of anandamide that exhibits weak or no binding to the human central cannabinoid (CB1) receptor (Ki >1 μM). It inhibits rat glial gap junction cell-cell communication 100% at a concentration of 50 μM.
|
-
- HY-N2327R
-
|
|
Reference Standards
Endogenous Metabolite
|
Others
|
|
Oleamide (Standard) is the analytical standard of Oleamide. This product is intended for research and analytical applications. Oleamide is an endogenous fatty acid amide which can be synthesized de novo in the mammalian nervous system, and has been detected in human plasma.
|
-
- HY-120369
-
|
|
FAAH
|
Neurological Disease
|
|
URB532 is an inhibitor for fatty acid amide hydrolase (FAAH) with an IC50 of 396 nM. URB532 increases levels of arachidonic acid acetamide (AEA), palmitoylethanolamide (PEA), and oleamide (OEA) in the rat brain, and exhibits anxiolytic and analgesic effects .
|
-
- HY-120300
-
|
|
Cannabinoid Receptor
|
Metabolic Disease
|
|
UCM710 is an endocannabinoid (eCB) hydrolysis inhibitor that increases the levels of N-arachidonoyl ethanolamine and 2-arachidonoylglycerol in neurons. UCM710 inhibits fatty acid amide hydrolase and α/β-hydrolase domain 6, but not monoacylglycerol lipase .
|
-
- HY-129932
-
|
|
Drug Derivative
|
Cancer
|
|
Pyrrolidine ricinoleamide ((R)-5d) is a fatty acid amide that exhibits effective antiproliferative activity against a series of cancer cells, including human glioma U251 cells. Pyrrolidine ricinoleamide can be used in cancer research .
|
-
- HY-15250R
-
|
|
FAAH
MAGL
Autophagy
|
Neurological Disease
|
|
JZL195 (Standard) is the analytical standard of JZL195. This product is intended for research and analytical applications. JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC50s of 2 and 4 nM, respectively .
|
-
- HY-134019
-
|
|
Others
|
Others
|
|
Arachidonoyl p-nitroaniline is a substrate for the hydrolysis of p-nitroaniline by FAAH in Dictyostelium discoideum with long-chain unsaturated fatty acids. Arachidonoyl p-nitroaniline can be used in enzyme kinetic studies. Examples include determining the hydrolysis rate of Arachidonoyl p-nitroaniline and analyzing the fatty acid amide hydrolase activity of recombinant His-FAAH purified from Dictyostelium to characterize the binding and catalytic specificity of mammalian FAAH enzymes .
|
-
- HY-14397AR
-
|
Indometacin sodium hydrate (Standard)
|
Reference Standards
COX
Bacterial
Influenza Virus
Antibiotic
|
Inflammation/Immunology
Cancer
|
|
Dimethenamide-P (Standard) is the analytical standard of Dimethenamide-P. This product is intended for research and analytical applications. Dimethenamide-P is an amide herbicide effective for the pre-emergence management of annual grasses, small-seeded broadleaf weeds, and sedges in ornamental plants, functioning by inhibiting the synthesis of long-chain fatty acids.
|
-
- HY-116710
-
|
|
FAAH
|
Others
|
|
3-Decyl-5,5'-diphenyl-2-thioxo-4-imidazolidinone (compound 45) is a potential inhibitor of fatty acid amide hydrolase (FAAH) (pI50: 5.89) and is active against CB(1) and CB(2) ) Lack of affinity for cannabinoid receptors .
|
-
- HY-124242
-
|
|
Drug Derivative
|
Cancer
|
|
(S)-α-Methylbenzyl ricinoleamide (compound (R,S)-3d) is a fatty acid amide. (S)-α-Methylbenzyl ricinoleamide shows antiproliferative activity, inhibits the growth of human ovarian cancer cells NCI-ADR/RES and glioma cells U251 with GI50s of 1.9 μg/mL and 3.6 μg/mL, respectively .
|
-
- HY-121465
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Stearoyl serotonin is a hybrid molecule patterned after arachidonoyl serotonin. Arachidonoyl serotonin is a dual antagonist of fatty acid amide hydrolase (FAAH) and the transient receptor potential vanilloid-type 1 (TRPV1) channel, reducing both acute and chronic peripheral pain. The effects of replacing the arachidonoyl portion with the saturated 18-carbon stearoyl moiety have not been studied. However, replacement of arachidonate with saturated 11- or 12-carbon fatty acids produces compounds that potently inhibit capsaicin-induced TRPV1 channel activation (IC50=0.76 μM) without blocking FAAH-mediated hydrolysis of arachidonoyl ethanolamine (IC50 > 50 μM).
|
-
- HY-121389R
-
|
PalmitAmide (Standard)
|
Bacterial
NF-κB
PPAR
Reference Standards
|
Infection
Inflammation/Immunology
|
|
Hexadecanamide (Standard) is the analytical standard of Hexadecanamide. This product is intended for research and analytical applications. Hexadecanamide (Palmitamide) is a fatty acid amide that has orally active anti-allergic, antioxidant, and neuroprotective effects. Hexadecanamide exerts protective effects in Staphylococcus aureus- and SARA-induced mastitis. Hexadecanamide suppresses S. aureus-induced activation of the NF-κB pathway and improves blood-milk barrier integrity. Hexadecanamide activates PPARα. Hexadecanamide enhances sperm motility in vitro. Hexadecanamide can be studied in research for mastitis and asthenozoospermia .
|
-
- HY-115004
-
|
|
FAAH
|
Neurological Disease
|
|
MM-433593 is a potent and selective inhibitor of fatty acid amide hydrolase-1 (FAAH-1) that is orally administered to inhibit pain, inflammation, and related disorders. Pharmacokinetic studies of MM-433593 in macaques revealed a biphasic elimination profile with a rapid distribution phase and a slower elimination phase, with a systemic clearance of 8-11 mL/min/kg. MM-433593 exhibits moderate oral bioavailability (14-21%) and its metabolism primarily involves oxidation of the methyl group on the indole ring, resulting in a variety of sulfate, glucuronide, or glutathione-conjugated metabolites .
|
-
- HY-181463
-
|
|
TRP Channel
FAAH
|
Others
|
|
20-Hydroxy-N-arachidonoyl taurine (Compound C20:4 NAT) acts as an activator of TRPV1 and TRPV4, with EC50 values of 28 µM and 21 µM, respectively. 20-Hydroxy-N-arachidonoyl taurine serves as a substrate for fatty acid amide hydrolase (FAAH) .
|
-
- HY-W742938
-
|
|
Drug Derivative
|
Others
|
|
(R)-(+)-Docosahexaenyl-1'-hydroxy-2'-propylamide is a polyunsaturated fatty acid amide with anti-proliferative properties.
|
-
- HY-W669241
-
|
|
Herbicide
|
Others
|
|
Dimethenamide-P is an amide herbicide effective for the pre-emergence management of annual grasses, small-seeded broadleaf weeds, and sedges in ornamental plants, functioning by inhibiting the synthesis of long-chain fatty acids.
|
-
- HY-184029
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PF-7845yne is a clickable analogue of PF-7845. PF-7845yne serves as a pharmacological probe to investigate effects of targeting the FAAH-anandamide pathway .
|
-
- HY-W669241R
-
|
|
Endogenous Metabolite
Reference Standards
|
Others
|
|
Dimethenamide-P (Standard) is the analytical standard of Dimethenamide-P. This product is intended for research and analytical applications. Dimethenamide-P is an amide herbicide effective for the pre-emergence management of annual grasses, small-seeded broadleaf weeds, and sedges in ornamental plants, functioning by inhibiting the synthesis of long-chain fatty acids.
|
-
- HY-101457R
-
|
|
MAGL
Reference Standards
|
Metabolic Disease
|
|
JZP-430 (Standard) is the analytical standard of JZP-430 (HY-101457). This product is intended for research and analytical applications. JZP-430 is a potent, highly selective, irreversible inhibitor of α/β-hydrolase domain 6 (ABHD6) with an IC50 of 44 nM, exhibits ~230-fold selectivity over fatty acid amide hydrolase (FAAH) and lysosomal acid lipase (LAL) .
|
-
- HY-10865R
-
|
|
Reference Standards
FAAH
Autophagy
|
Neurological Disease
|
|
LY2183240 (Standard) is the analytical standard of LY2183240 (HY-10865). This product is intended for research and analytical applications. LY2183240 is a highly potent blocker of anandamide uptake (IC50= 270 pM; Ki=540 nM). LY2183240 is a potent, covalent inhibitor of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) with an IC50 of 12.4 nM. LY2183240 inactivates FAAH by carbamylation of the enzyme's serine nucleophile. LY2183240 also inhibits several other brain serine hydrolases with IC50s of 5.3, 0.09, 8.2 nM for MAG lipase, bh6 and KiAA1363, respectively .
|
-
- HY-182589
-
|
|
FAAH
Potassium Channel
|
Neurological Disease
Metabolic Disease
|
|
SRP-001 is an orally active, blood-brain barrier-permeable analgesic and antipyretic agent. SRP-001 reduces the expression level of FAAH, mildly inhibits hERG currents, generates AM404 (HY-101388), and maintains the integrity of hepatic tight junctions. SRP-001 exerts analgesic, antipyretic, and antinociceptive effects .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-117401
-
|
|
Fluorescent Dyes
|
|
5-Dodecanoylaminofluorescein is an amphipathic (amphoteric) fluorescent probe (Ex/Em = 485 nm/515-535 nm), which consists of a hydrophilic fluorescein core and a hydrophobic dodecanoyl group (C12 fatty acid chain) linked by an amide bond. 5-Dodecanoylaminofluorescein is mainly used as an interface-localized radical trapping/indicator probe. Dodecanoylaminofluorescein can be used for the determination of the antioxidant properties of emulsions, or can serve as a lipophilic drug model for the study of passive skin penetration when encapsulated in tyrosine-derived nanospheres .
|
-
- HY-W479534
-
|
DemNA
|
Fluorescent Dyes
|
|
Decanoyl m-Nitroaniline (DemNA) is a nitroaniline fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity (Ab = 410 nm).
|
-
- HY-120971
-
|
DepNA
|
Fluorescent Dyes
|
|
N-Decanoyl p-nitroaniline (DepNA) is one of several nitroaniline fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity.1 FAAH is a relatively unselective enzyme in that it accepts a variety of amide head groups other than the ethanolamine of its endogenous substrate anandamide (AEA). It also will hydrolyze fatty acid amides with fewer carbons and fewer double bonds than arachidonate. Exposure of DepNA to FAAH activity results in the release of the yellow colorimetric dye p-nitroaniline (ε=13,500 at 410 nm). This allows the fast and convenient measurement of FAAH activity using a 96 well plate spectrophotometer.
|
| Cat. No. |
Product Name |
Type |
-
- HY-32952
-
|
6-Fluoropyridine-3-boronic Acid
|
Biochemical Assay Reagents
|
|
2-Fluoropyridine-5-boronic acid (6-Fluoropyridine-3-boronic acid) is a drug intermediate that can be used in the synthesis of fatty acid amide hydrolase inhibitors and pyrethroid derivatives .
|
-
- HY-133824
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-124081
-
|
|
Apoptosis
|
Metabolic Disease
|
|
N-Oleoyl-L-Serine is an endogenous amide of long-chain fatty acids with ethanolamine (N-acyl amides). N-Oleoyl-L-Serine is a lipid regulator of bone remodeling and stimulates osteoclast apoptosis. N-Oleoyl-L-Serine can be used for antiosteoporotic drug discovery development .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N2327
-
-
-
- HY-14595
-
-
-
- HY-121389
-
-
-
- HY-W130610
-
-
-
- HY-N2365
-
-
-
- HY-N6723
-
-
-
- HY-W130610R
-
-
-
- HY-14595R
-
-
-
- HY-W751418
-
|
(Z)-2-tetracos-15-enamidoethanesulfonic Acid
|
Natural Products
Endogenous metabolite
Source Classification
|
FAAH
|
|
N-Nervonoyl taurine ((Z)-2-tetracos-15-enamidoethanesulfonic acid) is a fatty acid-taurine conjugate derived from nervonic acid. N-Nervonoyl taurine is a substrate of fatty acid amide hydrolase (FAAH) discovered during metabolite profiling .
|
-
-
- HY-N3033
-
-
-
- HY-N7214
-
-
-
- HY-N2365R
-
-
-
- HY-N2512R
-
-
-
- HY-N15826
-
|
|
Lipid
|
Fluorescent Dye
Ceramidase
|
|
RBM1-151, a 1-deoxy derivative and vinilog of RBM14-C12 (HY-150163), as a fluorogenic substrate of Amidases (HY-P2736) (Ex/Em). RBM1-151 is hydrolyzed by acid ceramidase (AC) (( appKm = 7.0 μM; appVmax = 99.3 nM/min), N-acylethanolamine-hydrolyzing acid amidase ( appKm = 0.73 μM; appVmax = 0.24 nM/min), and fatty Acid amide hydrolase (FAAH) ( appKm = 3.6 μM; appVmax = 7.6 nM/min) but not by other ceramidases. RBM1-151 is applicable for basic biological studies of lipid amidase function, as well as potential diagnostic/prognostic evaluations of diseases involving dysregulated AC, NAAA, or FAAH (Farber disease, cancer) .
|
-
-
- HY-N2327R
-
-
-
- HY-121389R
-
|
PalmitAmide (Standard)
|
Structural Classification
Alkaloids
Cannabis sativa L
Other Alkaloids
Plants
Moraceae
Source Classification
|
Bacterial
NF-κB
PPAR
Reference Standards
|
|
Hexadecanamide (Standard) is the analytical standard of Hexadecanamide. This product is intended for research and analytical applications. Hexadecanamide (Palmitamide) is a fatty acid amide that has orally active anti-allergic, antioxidant, and neuroprotective effects. Hexadecanamide exerts protective effects in Staphylococcus aureus- and SARA-induced mastitis. Hexadecanamide suppresses S. aureus-induced activation of the NF-κB pathway and improves blood-milk barrier integrity. Hexadecanamide activates PPARα. Hexadecanamide enhances sperm motility in vitro. Hexadecanamide can be studied in research for mastitis and asthenozoospermia .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-184029
-
|
|
|
Alkynes
|
|
PF-7845yne is a clickable analogue of PF-7845. PF-7845yne serves as a pharmacological probe to investigate effects of targeting the FAAH-anandamide pathway .
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-169794
-
|
|
|
Cationic Lipids
|
|
N-Palmitoyl-phenylalanine is an N-acyl amide that contains the long-chain saturated fatty acid Palmitic acid (HY-N0830) conjugated via an amide bond to the essential amino acid L-Phenylalanine (HY-N0215). N-Palmitoyl-phenylalanine inhibits pre-mRNA splicing in HeLa cell nuclear lysates (IC50 > 400 μM) but has no splicing activity in intact HeLa cells .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: